On January 10, 2020, Pomerantz LLP was appointed Lead Counsel in a securities class action lawsuit against Zynerba Pharmaceuticals, Inc., regarding allegations that Zynerba failed to disclose details discovered in trials of its transdermal CBD gel product, Zygel.
Back to Pomerantz News